Halozyme CEO Executes 10b5-1 Plan, Sells 60,000 Shares After Exercise
Rhea-AI Filing Summary
Helen Torley, President and CEO and a director of Halozyme Therapeutics (HALO), exercised a total of 60,000 stock options at an $8.11 exercise price and concurrently sold the resulting 60,000 common shares over three days. The sales were executed at weighted-average prices reported in ranges between $62.54 and $64.96 per share, and the Form reports 733,719 shares beneficially owned by the reporting person following these transactions.
The filings state the transactions were made under a written Rule 10b5-1 trading plan adopted March 21, 2025, and that the sold shares were acquired upon exercise of options with ten-year terms expiring in February 2026. The underlying options were originally granted February 3, 2016, with a four-year vesting schedule.
Positive
- Trades executed under a Rule 10b5-1 plan, indicating pre-established, documented trading intent
- Reporting person retains substantial ownership with 733,719 shares beneficially owned after the transactions
Negative
- None.
Insights
TL;DR: Insider exercised and sold 60,000 shares under a pre-established plan; remaining ownership remains sizable at 733,719 shares.
The reporting shows sequential exercises of 20,000 options on each of three days at an $8.11 strike, immediately followed by sales of the same 20,000-share blocks at weighted-average prices within the $62.54–$64.96 range. Net effect: the CEO realized proceeds from option exercise and sale while ending with 733,719 shares beneficially owned. Transactions were executed under a documented 10b5-1 plan, which typically reduces the likelihood of opportunistic timing concerns. Overall, the activity is routine and not immediately material to Halozyme’s capital structure.
TL;DR: Trades were pre-planned under a Rule 10b5-1 plan; disclosure is complete and includes price ranges and option grant details.
The Form discloses that the sales were made pursuant to a written trading plan adopted March 21, 2025, and that the shares sold derived from option exercises of grants dated February 3, 2016. The filing includes explicit weighted-average price ranges for each sale block and shows post-transaction beneficial ownership of 733,719 shares. From a governance perspective, the documentation and level of disclosure align with standard compliance practices for insider transactions.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Option to Purchase Common Stock | 20,000 | $8.11 | $162K |
| Exercise | Common Stock | 20,000 | $8.11 | $162K |
| Sale | Common Stock | 14,948 | $64.145 | $959K |
| Sale | Common Stock | 5,052 | $64.828 | $328K |
| Exercise | Option to Purchase Common Stock | 20,000 | $8.11 | $162K |
| Exercise | Common Stock | 20,000 | $8.11 | $162K |
| Sale | Common Stock | 13,042 | $63.242 | $825K |
| Sale | Common Stock | 6,958 | $64.001 | $445K |
| Exercise | Option to Purchase Common Stock | 20,000 | $8.11 | $162K |
| Exercise | Common Stock | 20,000 | $8.11 | $162K |
| Sale | Common Stock | 18,717 | $63.008 | $1.18M |
| Sale | Common Stock | 1,283 | $63.598 | $82K |
Footnotes (1)
- The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026. Represents a weighted average sales price per share. The shares were sold at prices ranging from $62.54 to $63.53. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $63.54 to $63.63. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $62.68 to $63.67. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $63.745 to $64.24. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $63.70 to $64.69. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents a weighted average sales price per share. The shares were sold at prices ranging from $64.70 to $64.96. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 3, 2016.
